Poseida Therapeutics, Inc.
4250 Campus Point Court
Suite 700
San Diego
California
92121
United States
Website: http://poseida.com/
Email: info@poseida.com
87 articles with Poseida Therapeutics, Inc.
-
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors
5/18/2022
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Charles M. Baum , M.D., Ph.D., to its Board of Directors, effective May 16, 2022.
-
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
5/17/2022
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting.
-
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022
5/12/2022
Poseida Therapeutics, Inc. announced updates and financial results for the first quarter ended March 31, 2022.
-
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
5/2/2022
Poseida Therapeutics, Inc. announced that preclinical data highlighting the use of anti-c-kit CAR-T cells, P-ckit-ALLO1 as a preconditioning agent to enable hematopoietic stem cell transplants, will be presented at the American Society of Gene and Cell Therapy 25th Annual Meeting, being held in Washington, D.C. and virtually on May 16-19, 2022.
-
Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference
4/28/2022
Poseida Therapeutics, Inc. today announced that the Company's Chief Executive Officer, Mark Gergen, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 2:40pm PT in Las Vegas.
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021
3/10/2022
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and financial results for the fourth quarter and full year ended December 31, 2021.
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 02, 2022
3/2/2022
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Compensation Committee of its Board of Directors granted an inducement award to Brent Warner, the Company's new President, Gene Therapy.
-
BioSpace Movers & Shakers, Feb. 25
2/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
2/23/2022
Poseida Therapeutics, Inc. (NASDAQ: PSTX), today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy
2/22/2022
Poseida Therapeutics, Inc. today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022 .
-
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium
2/17/2022
Poseida Therapeutics, Inc. today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC).
-
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022
2/9/2022
Poseida Therapeutics, Inc. today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday February 23, 2022.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen
1/10/2022
Poseida Therapeutics, Inc. today announced the appointment of Eric Ostertag as Executive Chairman and the transition of current President and Chief Business Officer, Mark Gergen, to the role of Chief Executive Officer effective as of February 1, 2022.
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
12/20/2021
Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company's allogeneic CAR-T product candidate targeting multiple solid tumor indications.
-
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
12/13/2021
Poseida Therapeutics, Inc. (Nasdaq: PSTX), today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 2021 American Society of Hematology (ASH) Annual Meeting.
-
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
-
Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.